DR. THOMAS H. ESTEP, MD

Plain English
This research looked at a program where college students in Baltimore were trained to teach nutrition to low-income kids aged 10 to 14 to help fight childhood obesity. They found that while the program was beneficial, challenges like transportation issues and attracting youth participants needed to be addressed. By improving training and offering better incentives, the program could become more sustainable and continue to empower local high school students to lead these efforts. Who this helps: This helps low-income children and community leaders aiming to improve health in Baltimore.

Plain English
In March 2006, a workshop gathered scientists to discuss challenges in creating blood substitutes called hemoglobin-based oxygen carriers (HBOCs). They found that while HBOCs have potential, they often cause harmful side effects, especially related to heart health. The group emphasized the need for more research to understand these side effects and improve HBOCs, targeting better safety and effectiveness. Who this helps: This benefits patients needing blood transfusions and doctors involved in transfusion practices.

Plain English
This study looked at the safety of a treatment called diaspirin cross-linked hemoglobin (DCLHb), which is designed to help deliver oxygen in the body. Researchers found that some animals, like rhesus monkeys and pigs, developed heart muscle damage after receiving DCLHb, with less than 3% of their heart affected, but no serious health issues were noted. Importantly, using a modified version of the hemoglobin that interacts differently with nitric oxide led to fewer heart lesions, highlighting a key factor in preventing this damage. Who this helps: This research benefits patients who might receive hemoglobin-based oxygen treatments in the future.

Plain English
This study examined a heating process used to make a treatment called DCLHb, which is designed to help with blood supply, by ensuring it can kill viruses. Researchers tested how well this heat treatment worked against five different viruses, including HIV and Hepatitis A, and found that the process was very effective, reducing virus levels by at least 99.99999% (a 7 log reduction). This is important because it confirms that the treatment is safe from harmful viruses, ensuring better health outcomes for patients requiring this blood product. Who this helps: Patients needing blood treatments.

Plain English
This study looked at how heat treatment affects the inactivation of viruses during the production of a blood product called diaspirin crosslinked hemoglobin (DCLHb). Researchers found that both a non-enveloped virus (Porcine Parvovirus) and an enveloped virus (Bovine Viral Diarrhea Virus) were effectively inactivated by the heat treatment, with no impact from the crosslinking step. The experiments showed consistent results with large-scale production, confirming that the process is safe and effective for eliminating viruses. Who this helps: This helps patients who need blood products, ensuring their safety from viral infections.

Plain English
This study looked at how well a fluid called Diaspirin Crosslinked Hemoglobin (DCLHb) works for treating severe blood loss in pigs. The researchers found that using DCLHb helped increase blood pressure more rapidly than other treatments, boosting it from 48 to 102 mmHg within 10 minutes and maintaining better blood flow and oxygen levels for at least 2 hours. This is important because it shows that DCLHb could make a significant difference in emergency situations where stopping bleeding and maintaining blood pressure is crucial. Who this helps: This benefits patients experiencing severe blood loss and the medical professionals treating them.

Plain English
Researchers studied a blood substitute called diaspirin cross-linked hemoglobin (DCLHb) to ensure it can be reliably produced and stored for testing. They successfully produced this solution and showed it remained stable for over a year while stored in a frozen state. This finding is important because it confirms that DCLHb can be consistently produced and maintained for further research, which may lead to new treatments for patients who need blood transfusions. Who this helps: This helps patients who need blood products, doctors, and researchers investigating alternatives to traditional blood transfusions.

Plain English
This study looked at the presence of trace elements in a treatment called diaspirin cross-linked hemoglobin (DCLHb), which is used to help patients with blood loss. Researchers found that calcium, magnesium, zinc, and iron were the main elements present, with iron levels typically at 0.5-1.0 ppm for chelatable iron and 0.1-0.3 ppm for free non-heme iron. Understanding these trace elements is important because it helps ensure the safety and effectiveness of DCLHb for patients, particularly in critical medical situations. Who this helps: This helps patients who need blood substitutes and the doctors administering these treatments.

Plain English
This study looked at how different blood substitutes (specifically diaspirin cross-linked hemoglobin or DCLHb, human serum albumin, and erythrocyte hemolysate) affect sheep's heart and lung functions, as well as their blood and immune responses. The researchers found that sheep tolerated infusions of DCLHb and human serum albumin well, with no significant increase in inflammation markers. However, erythrocyte hemolysate caused a very high inflammatory response, increasing certain markers over 6000 times. This matters because it shows that DCLHb is a safer option for blood replacement without causing unwanted inflammation. Who this helps: This helps patients needing blood transfusions and doctors choosing safer blood substitutes.